Posterior Fossa Mutism on Quality of Life

Only registered users can translate articles

The link is saved to the clipboard

StatusCompleted

Keywords

Abstract

Posterior fossa mutism (PFM) occurs in up to 30% of patients after resection of a posterior fossa tumor, most commonly a medulloblastoma. PFM is characterized by delayed onset of mutism 1-6 days after surgery that can spontaneously improve on average from 7-8 weeks later. Few patients recover normal speech. Most of their speech continues to be marked by dysarthria, dysfluency and slowed rate. Researchers have not identified the pathophysiologic mechanism for PFM nor have they found a cure. Despite the improvements in speech, patients with PFM have shown multiple areas of neurocognitive deficits 12 months after diagnosis. Few studies have looked at long term outcomes of patients affected by PFM. We propose to survey patients who developed PFM after resection of a medulloblastoma to determine long term effects of PFM on patient's quality of life.

Dates

Last Verified:	01/31/2016
First Submitted:	01/26/2014
Estimated Enrollment Submitted:	01/26/2014
First Posted:	01/28/2014
Last Update Submitted:	02/02/2016
Last Update Posted:	02/04/2016
Actual Study Start Date:	06/30/2011
Estimated Primary Completion Date:	02/29/2012
Estimated Study Completion Date:	02/29/2012

Condition or disease

Posterior Fossa Mutism

Phase

Arm Groups

Arm	Intervention/treatment
Posterior Fossa Mutism Patients with Posterior Fossa Mutism
Non Posterior Fossa Mutism Patients that did not develop Mutism

Eligibility Criteria

Ages Eligible for Study	8 Years To 8 Years
Sexes Eligible for Study	All
Sampling method	Non-Probability Sample
Accepts Healthy Volunteers	Yes
Criteria	Inclusion Criteria: Patients must be between 8 years and 25 years of age at the time of enrollment and have completed treatment for their initial diagnosis of medulloblastoma. Exclusion Criteria: 1. Patient is less than 8 years old or greater than 25 years old at the time of the administration of the survey. 2. Patients are too ill to complete the survey as identified by their treating physician. 3. Patients who are unable to speak or understand English. 4. Patients who are currently being treated for their original diagnosis of medulloblastoma.

Outcome

Primary Outcome Measures

1. Quality of Life [Thirty minutes, no follow-up.]

Secondary Outcome Measures

1. quality of life in terms of anger, anxiety, depression, fatigue, social functioning, pain and stigma [30 minutes, no follow-up]

Posterior Fossa Mutism on Quality of Life

Keywords

neoplasms

medulloblastoma

dysarthria

mutism